Novartis AG (NVS) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an esta...
Novartis AG (NVS) currently trades at a P/E ratio of 21.56 (historical range: 21.09–22.41, median: 21.77), placing it at the 24th percentile — below its historical average, P/S ratio of 5.32 (range: 5.20–5.53, 24th percentile — below its historical average), EV/EBITDA of 18.44 (range: 18.07–19.12, 24th percentile).
Novartis AG appears significantly undervalued relative to its historical range, trading at depressed multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 21.56 | 21.09 | 21.77 | 22.41 | 24th | below its historical average |
| P/S Ratio | 5.32 | 5.20 | 5.37 | 5.53 | 24th | below its historical average |
| EV/EBITDA | 18.44 | 18.07 | 18.60 | 19.12 | 24th | below its historical average |